Anti-endotoxin properties of cationic host defence peptides and proteins

Abstract

The innate immune system of mammals contains a series of peptides with overall positive charge and an amphipathic structure which have a variety of important properties in host defences. Although these are often termed cationic antimicrobial peptides, they have numerous roles in innate defences in all complex species of life and thus we prefer to refer to them as host defence peptides. These roles include: (i) an ability to kill micro-organisms directly, ranging from bacteria to viruses, fungi, parasites and helminths; (ii) an adjuvant activity in the adaptive response; and (iii) a multiplicity of roles in modulating innate immunity, including an apparent ability to stimulate protective innate immunity while suppressing harmful inflammatory/septic responses. This latter property may be one of the more important activities of these peptides in vivo. Innate immunity is thought to be triggered by the interaction of conserved bacterial components with particular receptors including Toll-like receptors (TLRs) on host cells. However, the initiation of the innate immune response through this route may trigger a pro-inflammatory cascade that is the principle cause of harmful conditions such as sepsis. Since we are exposed to potentially dangerous pathogens on a daily basis, the host response must contain certain checks and balances. We propose that host defence peptides have a role in feed-back modulation of inflammation under normal (low-pathogen exposure) conditions. This review surveys the available information regarding the antiendotoxic/anti-inflammatory properties of host defence peptides, and will address whether this potential might be exploited for therapeutic benefit in sepsis.

Keywords

Host defence peptides sepsis immunomodulator endotoxin

References

Natanson C. , Esposito CJ , Banks SM The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998; 26: 1927—1931.

Friedman G. , Silva E. , Vincent JL Has the mortality of septic shock changed with time. Crit Care Med 1998; 26: 2078—2086.

Angus DC , Linde-Zwirble WT , Lidicker J. , Clermont G. , Carcillo J. , Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303—1310.

Levy MM , Fink MP , Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250—1256.

Harris BH , Gelfand JA The immune response to trauma. Semin Pediatr Surg 1995; 4: 77—82.

Frank ED , Kaufman D. , Korman H. , Schweinburg F. , Frank HA , Fine J. Effect of antibiotics on hemodynamics of hypovolemic septic shock. Am J Physiol 1955; 182: 166—176.

Periti P. , Mazzei T. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Int J Antimicrob Agents 1999; 12: 97—105.

Polderman KH , Girbes AR Drug intervention trials in sepsis: divergent results. Lancet 2004; 363: 1721—1723.

Sevransky JE , Parent C. , Cui X. et al. Granulocyte colony-stimulating factor has differing effects comparing intravascular versus extravascular models of sepsis. J Trauma 2004; 57: 618—625.

10.

Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003 ; 7: 108—114.

11.

Hawkins LD , Christ WJ , Rossignol DP Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4: 1147—1171.

12.

Diamond G. , Russell JP , Bevins CL Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc Natl Acad Sci USA 1996; 93: 5156—5160.

13.

Nell MJ , Sandra Tjabringa G , Vonk MJ , Hiemstra PS , Grote JJ Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol Med Microbiol 2004; 42: 225—231.

14.

De Y. , Chen Q. , Schmidt AP et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069—1074.

15.

Elssner A. , Duncan M. , Gavrilin M. , Wewers MD A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004; 172: 4987—4994.

16.

Scott MG , Hancock Rew. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 2000; 20: 407—431.

17.

Davidson DJ , Currie AJ , Reid GS et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146—1156.

18.

van Wetering S. , Mannesse-Lazeroms SP , van Sterkenburg MA , Hiemstra PS Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm Res 2002; 51: 8—15.

19.

Lau YE , Rozek A. , Scott MG , Goosney DL , Davidson DJ , Hancock Rew. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 2005 ; 73: 583—591.

20.

Yang D. , Chen Q. , Hoover DM et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003; 74: 448—455.

21.

Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39—48.

22.

Powers JP , Hancock Rew. The relationship between peptide structure and antibacterial activity. Peptides 2003; 24: 1681—1691.

23.

Larrick JW , Hirata M. , Zheng H. et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994; 152: 231—240.

24.

Larrick JW , Hirata M. , Balint RF , Lee J. , Zhong J. , Wright SC Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995; 63: 1291—1297.

25.

VanderMeer TJ , Menconi MJ , Zhuang J. et al. Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs. Surgery 1995; 117: 656—662.

26.

Kirikae T. , Hirata M. , Yamasu H. et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 1998; 66: 1861—1868.

27.

Scott MG , Vreugdenhil AC , Buurman WA , Hancock Rew , Gold MR Cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000; 164: 549—553.

28.

[see 26]

29.

Scott MG , Davidson DJ , Gold MR , Bowdish D. , Hancock Rew. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169: 3883—3891.

30.

Ohgami K. , Ilieva IB , Shiratori K. et al. Effect of human cationic antimicrobial protein 18 peptide on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2003; 44: 4412—4418.

31.

Giacometti A. , Cirioni O. , Ghiselli R. et al. The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit Care Med 2004; 32: 2485—2490.

32.

Rogy MA , Oldenburg HS , Calvano SE et al. The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol 1994; 14: 120—133.

33.

Scott MG , Gold MR , Hancock Rew. Interaction of cationic peptides with lipoteichoic acid and Gram-positive bacteria. Infect Immun 1999; 67: 6445—6453.

34.

Britigan BE , Lewis TS , Waldschmidt M. , McCormick ML , Krieg AM Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 2001; 167: 2921—2928.

35.

Weiss J. , Franson RC , Beckerdite S. , Schmeidler K. , Elsbach P. Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest 1975; 55: 33—42.

36.

Elsbach P. , Weiss J. , Franson RC , Beckerdite-Quagliata S. , Schneider A. , Harris L. Separation and purification of a potent bactericidal/ permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem 1979; 254: 11000—11009.

37.

Weiss J. , Muello K. , Victor M. , Elsbach P. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 1984; 132: 3109—3115.

38.

Tobias PS , Mathison JC , Ulevitch RJ A family of lipopolysaccharide binding proteins involved in responses to Gram-negative sepsis. J Biol Chem 1988; 263: 13479—13481.

39.

Marra MN , Wilde CG , Griffith JE , Snable JL , Scott RW Bactericidal/ permeability-increasing protein has endotoxin-neutralizing activity . J Immunol 1990; 144: 662—666.

40.

Beamer LJ , Carroll SF , Eisenberg D. The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions . Biochem Pharmacol 1999; 57: 225—229.

41.

Ooi CE , Weiss J. , Elsbach P. , Frangione B. , Mannion B. A 25-kDa NH2terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem 1987; 262: 14891—14894.

42.

Gazzano-Santoro H. , Parent JB , Grinna L. et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60: 4754—4761.

43.

Jiang Z. , Hong Z. , Guo W. et al. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 2004; 4: 527—537.

44.

Ciornei CD , Egesten A. , Engstrom M. , Tornebrandt K. , Bodelsson M. Bactericidal/permeability-increasing protein inhibits endotoxin-induced vascular nitric oxide synthesis. Acta Anaesthesiol Scand 2002; 46: 1111—1118.

45.

Kluger MS

Vascular endothelial cell adhesion and signaling during leukocyte recruitment. Adv

Dermatol 2004; 20: 163—201.

46.

Kakkar AK , Lefer DJ Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004; 4: 154—158.

47.

Huang K. , Fishwild DM , Wu HM , Dedrick RL Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein. Inflammation 1995; 19: 389—404.

48.

Marra MN , Wilde CG , Collins MS , Snable JL , Thornton MB , Scott RW The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532—537.

49.

Meszaros K. , Parent JB , Gazzano-Santoro H. et al. A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J Leukoc Biol 1993; 54: 558—563.

50.

Corradin SB , Heumann D. , Gallay P. , Smith J. , Mauel J. , Glauser MP Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide . J Infect Dis 1994; 169: 105—111.

51.

Weiss J. , Elsbach P. , Shu C. et al. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria . J Clin Invest 1992; 90: 1122—1130.

52.

Jiang J. , Zhu P. , Wang Z. et al. Protective effect of bactericidal/ permeability-increasing protein in mice with E. coli sepsis. Chin J Traumatol 1998; 1: 21—24.

53.

Jiang J. , Xie G. , Liu D. et al. Effect of bactericidal/permeability-increasing protein on sepsis induced by intra-abdominal infection in rats. Chin J Traumatol 1999; 2: 84—86.

54.

Kohn FR , Ammons WS , Horwitz A. et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J Infect Dis 1993; 168: 1307—1310.

55.

Vandermeer TJ , Menconi MJ , O'Sullivan BP et al. Bactericidal/ permeability-increasing protein ameliorates acute lung injury in porcine endotoxemia. J Appl Physiol 1994; 76: 2006—2014.

56.

Kartalija M. , Kim Y. , White ML , Nau R. , Tureen JH , Tauber MG Effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein (rBPI23) on cerebrospinal fluid inflammation induced by endotoxin. J Infect Dis 1995; 171: 948—953.

57.

Rogy MA , Moldawer LL , Oldenburg HS et al. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg 1994; 220: 77—85.

58.

Giroir BP , Quint PA , Barton P. et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350: 1439—1443.

59.

Levin M. , Quint PA , Goldstein B. et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356: 961—967.

60.

Sorensen OE , Follin P. , Johnsen AH et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951—3959.

61.

Turner J. , Cho Y. , Dinh NN , Waring AJ , Lehrer RI Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998 ; 42: 2206—2214.

62.

Nagaoka I. , Hirota S. , Niyonsaba F. et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001; 167: 3329—3338.

63.

Bowdish DM , Davidson DJ , Lau YE , Lee K. , Scott MG , Hancock Rew. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2004; 77: 451—459.

64.

Giacometti A. , Cirioni O. , Ghiselli R. et al. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am J Respir Crit Care Med 2004; 169: 187—194.

65.

Nagpal S. , Kaur KJ , Jain D. , Salunke DM Plasticity in structure and interactions is critical for the action of indolicidin, an antibacterial peptide of innate immune origin. Protein Sci 2002; 11: 2158—2167.

66.

Bowdish DM , Davidson, DJ , Scott M. , Hancock, Rew. Immunomodulatory activities of small host defence peptides. Antimicrob Agents Chemother 2005; 49: 1727—1732.

67.

Ciornei CD , Egesten A. , Bodelsson M. Effects of human cathelicidin antimicrobial peptide LL-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro. Acta Anaesthesiol Scand 2003; 47: 213—220.

68.

Fukumoto K. , Nagaoka I. , Yamataka A. et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr Surg Int 2005; 21: 20—24.

69.

Gough M. , Hancock Rew , Kelly NM Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64: 4922—4927.

70.

Sawyer JG , Martin NL , Hancock Rew. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Immun 1988; 56: 693—698.

71.

Hancock Rew , Chapple DS Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317—1323.

72.

Ferguson AD , Welte W. , Hofmann E. et al. A conserved structural motif for lipopolysaccharide recognition by procaryotic and eucaryotic proteins. Structure Fold Des 2000; 8: 585—592

73.

Andra J. , Koch MH , Bartels R. , Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother 2004; 48: 1593—1599.

74.

Scott MG , Rosenberger CM , Gold MR , Finlay BB , Hancock Rew. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression . J Immunol 2000; 165: 3358—3365.

75.

Giacometti A. , Cirioni O. , Ghiselli R. et al. Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob Agents Chemother 2002; 46: 2132—2136.

76.

Giacometti A. , Cirioni O. , Ghiselli R. et al. Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. Peptides 2003; 24: 1747—1752.

77.

Thomas JA , Tsen MF , White DJ , Horton JW TLR4 inactivation and rBPI(21) block burn-induced myocardial contractile dysfunction . Am J Physiol 2002; 283: H1645—H1655.